NYXH Nyxoah

Publication relating to transparency notifications

Publication relating to transparency notifications

                

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), May 9, 2025, 10:30 pm CET / 4:30 pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

FMR LLC

On May 2, 2025, Nyxoah received a transparency notification from FMR LLC. Based on the notification, FMR LLC (together with its controlled undertakings) holds 1,111,240 voting rights, consisting of 987,776 voting rights linked to securities and 123,464 equivalent financial instruments, representing 2.97% of the total number of voting rights on April 29, 2025 (37,427,265).

The notification dated May 2, 2025 contains the following information:

  • Reason for the notification:
    • Acquisition or disposal of voting securities or voting rights
    • Downward crossing of the lowest threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement: FMR LLC (with address at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.)
  • Date on which the threshold was crossed: April 29, 2025
  • Threshold that is crossed: 3%
  • Denominator: 37,427,265
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
FMR LLC00 0.00% 
Fidelity Management & Research Company LLC1,613,630773,382 2.07% 
FIAM LLC258258 0.00% 
FMR Investment Management (UK) Limited 214,136 0.57% 
Subtotal1,613,888987,776 2.64% 
 TOTAL987,776 2.64% 



B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
Fidelity Management & Research Company LLCStock Loan  123,4640.33%physical
 TOTAL  123,4640.33% 



 TOTAL (A & B)# of voting rights% of voting rights 
    1,111,2402.97% 
  • Full chain of controlled undertakings through which the holding is effectively held: FIAM LLC is controlled by FIAM Holdings LLC; FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC; FIAM Holdings LLC, Fidelity Management & Research Company LLC are controlled by FMR LLC; FMR LLC is not a controlled undertaking.



  • Additional information: The holdings attributed to the entities mentioned in the above section “Notified details” arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, FMR Investment Management (UK) Limited, and Fidelity Management & Research Company LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in the above section “Notified details” are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.



*

* *

Contact:

Nyxoah

John Landry, CFO



Attachment



EN
09/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 29, 2025, 10:45 pm CET / 4:45 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,432,066.28 Total number of securities carrying voting rights: 37,441,140 (all ordinary shares) Total number of voting rights (= denominator): 37,4...

 PRESS RELEASE

Informations sur le nombre total de droits de vote et d'actions

Informations sur le nombre total de droits de vote et d'actions INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 29 juillet 2025, 22:45h CET / 16:45h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publie les informations ci-dessous suite à l'émission de nouvelles actions. Capital: EUR 6.432.066,28 Nombre total de titres avec droits de vote: 37.441.140 (tous des actions ordinaires) Nombre total de droits d...

 PRESS RELEASE

Nyxoah Publiera ses Résultats Financiers du Second Trimestre 2025 le 1...

Nyxoah Publiera ses Résultats Financiers du Second Trimestre 2025 le 18 Août 2025 Nyxoah Publiera ses Résultats Financiers du Second Trimestre 2025 le 18 Août 2025 Mont-Saint-Guibert, Belgique – Mardi 29 juillet 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui a annoncé aujourd'hui que la Société publiera ses résultats financiers pour le second trimestre...

 PRESS RELEASE

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, ...

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss finan...

 PRESS RELEASE

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical...

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that data from its DREAM pivotal study was published online in the Journal of Clinical Sleep Medicine. The DREAM pivotal study presents comprehensive 1...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch